Compugen vs Champions Oncology
CGEN and CSBR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CGEN and CSBR compare
Compugen grew revenue faster over the last twelve months (161% versus 6.7% for Champions Oncology).
Compugen keeps more of each dollar of sales as profit, with a net margin of 48.6% compared with −1.8% at Champions Oncology.
Compugen scores higher on the StockData Score (12 against 9 for Champions Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CGEN | CSBR |
|---|---|---|
| Size and price | ||
| Market cap | – | $66.5M |
| Share price | $2.09 | $4.78 |
| Change, 1 year | 25.1% | −29.5% |
| Change, 5 years | −55.6% | −49.0% |
| Beta (5Y) | 1.60 | 0.36 |
| Employees | 2 | 214 |
| StockData Score | ||
| Total score | 12 (better) | 9 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 4 (better) | 3 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.1× |
| P/B | – | 17.1× |
| EV/EBITDA | – | 216× |
| FCF yield | – | −9.2% |
| Fair value | – | $1.36 |
| Margin of safety | – | −251% |
| Growth | ||
| Revenue growth (TTM) | 161% (better) | 6.7% |
| Revenue growth, 5Y average | 105% (better) | 7.7% |
| Net income growth (TTM) | – | −138% |
| EPS growth (TTM) | – | −140% |
| Profitability | ||
| Gross margin | 87.3% (better) | 49.8% |
| Operating margin | 43.1% (better) | −1.7% |
| Net margin | 48.6% (better) | −1.8% |
| FCF margin | 43.1% (better) | −10.1% |
| Return on equity | 50.9% (better) | −29.8% |
| Return on invested capital | 117% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.72 (better) | 1.03 |
| Altman Z-score | – | −0.30 |
| Piotroski F-score | 7 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 42.4% |
| Held by insiders | 0.43% | 30.5% |
| Insider net buying, 12 months | −$126K | – |
| Short interest, % of float | 2.7% | 0.75% |
Go deeper
- CGEN stock overview
- CGEN income statement
- CGEN valuation and score
- CSBR stock overview
- CSBR income statement
- CSBR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.